Trade Mark Journal No.2018/017 27 April 2018
WO0000001393810 (5,42)
Office of origin: United States
Date of International Registration:20 December 2017
Date of designation in the UK:
20 December 2017

International priority date claimed: 23 June 2017
(United States)
(87502704)
- Class 5
- Cells for medical or clinical use; pharmaceutical and biopharmaceutical agents for the treatment of cancer, infectious disease, autoimmune disorders, transplant rejections, and inflammatory disease; pharmaceutical and biopharmaceutical preparations and substances for the treatment of cancer, infectious disease, autoimmune disorders, transplant rejections, and inflammatory disease.
- Class 42
- Pharmaceutical, medical, scientific, and biopharmaceutical research and development.
Agenus Inc.
Representative: Christina M. Licursi Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston MA 02210-2206, UNITED STATES OF AMERICA